2024
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Lemelin A, Ernst M, Wells J, Saliby R, El Zarif T, Labaki C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Lalani A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Agarwal N, Choueiri T, Heng D. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology 2024 PMID: 38290965, DOI: 10.1016/j.eururo.2024.01.006.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumBrain metastasesRenal cell carcinomaStereotactic radiotherapyOverall survivalSystemic therapyCell carcinomaAssociated with longer median overall survivalAssociated with longer overall survivalInitiation of systemic therapyLonger median overall survivalAssociated with longer OSTyrosine kinase inhibitor monotherapyAssociated with better prognosisIO-based regimensMedian overall survivalWhole-brain radiotherapyFirst-line therapyAdvanced kidney cancerLonger overall survivalOutcomes of patientsGroup of patientsCombination immunotherapyLonger OSInhibitor monotherapy
2023
Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations. The Oncologist 2023, 28: s9-s10. PMCID: PMC10445590, DOI: 10.1093/oncolo/oyad216.014.Peer-Reviewed Original ResearchDisease control rateFirst-line ICIImmune checkpoint inhibitorsOverall survivalTime of presentationSynchronous diseaseTreatment failureRenal cell carcinomaMetachronous diseaseMetastatic diseaseRCC diagnosisFirst-line immune checkpoint inhibitorsMetastatic renal cell carcinoma patientsMultivariable Cox proportional hazards modelsLower disease control rateNon-clear cell histologyMetastatic renal cell carcinomaRenal cell carcinoma patientsCox proportional hazards modelIMDC risk scoresInitial RCC diagnosisSynchronous metastatic diseaseMedian overall survivalMedian TTFFirst-line treatmentThe impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Castro D, Tripathi N, Sayegh N, Gebrael G, Li X, Meza L, Zengin Z, Chehrazi-Raffle A, Govindarajan A, Dizman N, Ebrahimi H, Chawla N, Mercier B, BS J, Shi J, Philip E, Bergerot C, Barragan-Carrillo R, Pal S. The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). The Oncologist 2023, 28: s5-s6. PMCID: PMC10445577, DOI: 10.1093/oncolo/oyad216.008.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMedian progression-free survivalProgression-free survivalLog-rank testMedian overall survivalOverall survivalMedicaid/Insurance statusSecondary insurancePrivate insurancePrimary insuranceSystemic therapyClinical outcomesEntire cohortInferior median progression-free survivalSuperior median progression-free survivalSignificant differencesCox proportional hazards regression modelFirst-line systemic therapyMedicaid/uninsured patientsSuperior progression-free survivalProportional hazards regression modelsLine systemic therapyFirst-line treatmentKaplan-Meier methodCharacterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
Govindarajan A, Salgia N, Li H, Castro D, Mirzapoiazova T, Armstrong B, Zhao D, Mercier B, Dizman N, Chawla N, Zengin Z, Meza L, Tripathi N, Sayegh N, Chehrazi-Raffle A, Tripathi A, Pal S. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Frontiers In Immunology 2023, 14: 1182581. PMID: 37638025, PMCID: PMC10457014, DOI: 10.3389/fimmu.2023.1182581.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaCell renal cell carcinomaCell carcinomaT cellsTumor microenvironmentPRCC cohortCcRCC cohortCcRCC patientsMain immune cell typesDistinct immunologic profileRCC histological subtypesMedian overall survivalProportion of CD4Baseline tumor tissueImmune cell populationsSubtypes of RCCImmune cell typesMass cytometry analysisCross-validate findingsSignificant differencesFFPE samplesMacrophage compositionTME compartmentsReal-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma
Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal S, Onyshchenko M. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. The Oncologist 2023, 28: 1079-1084. PMID: 37432304, PMCID: PMC10712704, DOI: 10.1093/oncolo/oyad190.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaProgression-free survivalComprehensive cancer centerNivolumab/ipilimumabShorter progression-free survivalOverall survivalRenal cell carcinomaLatinx patientsMultivariate Cox proportional hazards regressionCox proportional hazards regressionSafety-net healthcare systemHope Comprehensive Cancer CenterFirst-line immunotherapyTertiary oncology centerImmune checkpoint inhibitorsLos Angeles County DepartmentMedian overall survivalKaplan-Meier methodProportional hazards regressionDifferent healthcare settingsReal-world outcomesCheckpoint inhibitorsData cutoffClinical outcomesHazards regressionImplications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
Leong S, Ali S, Zengin Z, Meza L, Dizman N, Ebrahimi H, Govindarajan A, Castro D, Li X, Kim T, Melamed S, Onyshchenko M, Pal S, Chehrazi-Raffle A. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). Journal Of Clinical Oncology 2023, 41: 613-613. DOI: 10.1200/jco.2023.41.6_suppl.613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalSafety-net healthcare systemComprehensive cancer centerShorter progression-free survivalHistory of nephrectomyTertiary care centerOverall survivalLatinx patientsMRCC patientsClinical outcomesCare centerHealthcare systemHope Comprehensive Cancer CenterPoor-risk diseaseTertiary oncology centerImmune checkpoint inhibitorsLos Angeles County DepartmentMedian overall survivalRisk classificationClear cell histologyFirst-line therapyNumber of comorbiditiesKaplan-Meier methodBody mass indexAssociation between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Li X, Agarwal N, Pal S. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 678-678. DOI: 10.1200/jco.2023.41.6_suppl.678.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMedian overall survivalOverall survivalHazard ratioPotential confoundersMedian TTFDisease outcomeMultivariate analysisCox proportional hazards modelEfficacy of ICIsObjective response ratePoor-risk diseaseProgression-free survivalSecond-line treatmentClear cell histologyRenal cell carcinomaProportional hazards modelBaseline characteristicsFree survivalCell histologyMedian ageRisk diseaseTreatment failureEntire cohortCell carcinoma
2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
Chawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall response rateTumor mutational burdenOverall survivalWorse OSPrimary diseaseMultivariate analysisMedian progression-free survivalImmune checkpoint inhibitor therapyInferior progression-free survivalPromoter mutationsWorse progression-free survivalCheckpoint inhibitor therapyMedian overall survivalImmune checkpoint inhibitorsTertiary cancer centerClinical prognostic factorsPrimary tumor siteTERT promoter mutationsCheckpoint inhibitorsInhibitor therapyLaboratory parametersPrognostic factorsCancer CenterFemale sexImaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Navani V, Ernst M, Wells J, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, Powles T, McKay R, Weickhardt A, Suarez C, Kapoor A, Lee J, Choueiri T, Heng D. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2022, 5: e2216379. PMID: 35687336, PMCID: PMC9187954, DOI: 10.1001/jamanetworkopen.2022.16379.Peer-Reviewed Original ResearchConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaIO combination therapyInternational Metastatic Renal Cell Carcinoma Database Consortium riskPresence of lung metastasesCombination therapyCytoreductive nephrectomyComplete responseStable diseasePartial responseOverall survivalLung metastasesProgressive diseaseImmuno-oncologyImaging responseDiagnosis of metastatic renal cell carcinomaVascular endothelial growth factor inhibitorsIncreased likelihood of responseMedian overall survivalResponse Evaluation CriteriaGrowth factor inhibitorsMulticenter international cohort studyRenal cell carcinomaLikelihood of responseInternational cohort studyPredictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counseling
2019
Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma
Bergerot P, Bergerot C, Philip E, Meza L, Dizman N, Hsu J, Pal S. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma. Kidney Cancer 2019, 3: 63-70. DOI: 10.3233/kca-180047.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorHigher body mass indexBody mass indexLower body mass indexMedian overall survivalOverall survivalMass indexMetastatic renal cell carcinoma patientsMetastatic renal cell carcinomaEffect of BMIRenal cell carcinoma patientsImproved overall survivalCell carcinoma patientsBetter overall survivalKaplan-Meier methodContext of immunotherapyRenal cell carcinomaPatients 66Median OSCarcinoma patientsClinical outcomesHigher BMIRetrospective studyCell carcinomaClinical variables